Drugs / Camoteskimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 missed | ||||||
| Phase 1 | NCT04752371 | Mar 2021 → May 2022 | adult-onset Still disease | Apollo Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT04671251 | Dec 2020 → Mar 2022 | plasma cell myeloma | Avalo Therapeutics, Inc. | Completed | Missed primary |
| Phase 1 | NCT01322594 | Mar → Nov 2011 | chronic obstructive pulmonary disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07599813 | May 2026 → Oct 2027 expected | atopic IgE-mediated allergic disorder, atopic eczema | Apollo Therapeutics Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06436183 | May 2024 → Mar 2025 | atopic eczema | Apollo Therapeutics Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-16 | Apollo Therapeutics Ltd | Results Apollo Therapeutics’ Anti-IL-18 Antibody Camoteskimab Met the Primary Endpoint in a Double-Blind, Randomized, Placebo-Controlled Phase 2a Clinical Trial in Atopic Dermatitis apollotx.com ↗
The double-blind, randomized, placebo-controlled trial (n=62) demonstrated clinically meaningful efficacy, achieving a statistically significant reduction in EASI (Eczema Area and Severity Index) PCFB (percentage change from baseline) at week 16 compared to placebo. |
| 2020-12-22 | Avalo Therapeutics, Inc. | Regulatory Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease December 22, 2020 1:00pm EST avalotx.com ↗
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat Still’s disease has been accepted by the United States Food and Drug Administration (FDA) and is now open. |
All press releases naming this drug 7 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Camoteskimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07599813 ↗ |
| Known as | AEVI-007 | “Camoteskimab (CERC-007, AVTX-007, AEVI-007)” NCT04752371 ↗ |
| Known as | AVTX-007 | “Camoteskimab (CERC-007, AVTX-007, AEVI-007)” NCT04752371 ↗ |
| Known as | CERC-007 | “Camoteskimab (CERC-007, AVTX-007, AEVI-007)” NCT04752371 ↗ |
| Known as | MEDI2338 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01322594 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109604 ↗ |
| Route | Intravenous | “MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose” NCT01322594 ↗ |
| Target | IL18 | “Interleukin-18 cross-linking agent” CHEMBL2109604 ↗ |